|
15 Sep 2025 |
Lupin
|
Consensus Share Price Target
|
2043.40 |
2224.81 |
- |
8.88 |
buy
|
|
|
|
|
16 May 2023
|
Lupin
|
Geojit BNP Paribas
|
2043.40
|
830.00
|
790.75
(158.41%)
|
Target met |
Hold
|
|
|
|
|
11 May 2023
|
Lupin
|
ICICI Direct
|
2043.40
|
740.00
|
765.45
(166.95%)
|
|
Hold
|
|
|
|
|
11 May 2023
|
Lupin
|
Axis Direct
|
2043.40
|
825.00
|
765.45
(166.95%)
|
Target met |
Buy
|
|
|
We get more confidence in Lupin's business due to the following factors 1.) New launches in the US market like Darunavir, Cynocobalamin, Diazepem Gel, Vereniciline, Bromfenac, etc. excl. gSpirva We have BUY Rating on the stock
|
|
11 May 2023
|
Lupin
|
Motilal Oswal
|
2043.40
|
640.00
|
765.45
(166.95%)
|
|
Sell
|
|
|
|
|
10 May 2023
|
Lupin
|
Prabhudas Lilladhar
|
2043.40
|
730.00
|
750.20
(172.38%)
|
|
Hold
|
|
|
|
|
14 Feb 2023
|
Lupin
|
Axis Direct
|
2043.40
|
735.00
|
663.00
(208.21%)
|
Target met |
Hold
|
|
|
Recommendation: We maintain HOLD on stock
|
|
13 Feb 2023
|
Lupin
|
ICICI Securities Limited
|
2043.40
|
634.00
|
675.15
(202.66%)
|
Target met |
Sell
|
|
|
Lupin’s Q3FY23 performance was a beat on revenue front led by better than expected US sales. Revenue grew 3.9% YoY and 4.3% QoQ to Rs43.2bn (I-Sec: Rs41.4bn). US revenue was up 11.3% QoQ at US$177mn (I-Sec:US$172mn) led by new product launches (~US$20mn) and benefit from flu season.
|
|
13 Feb 2023
|
Lupin
|
Prabhudas Lilladhar
|
2043.40
|
675.00
|
675.15
(202.66%)
|
Target met |
Hold
|
|
|
|
|
12 Feb 2023
|
Lupin
|
Motilal Oswal
|
2043.40
|
610.00
|
737.15
(177.20%)
|
|
Sell
|
|
|
|
|
11 Feb 2023
|
Lupin
|
ICICI Direct
|
2043.40
|
725.00
|
737.15
(177.20%)
|
Target met |
Hold
|
|
|
|